Flu vaccines are updated every year, but the 2026–27 season brings a notable change: an mRNA vaccine has joined the options available to some adults in the United States.
The vaccine, called MFLUSIVA, was developed by Moderna and is approved for adults aged 50 and older. Unlike traditional flu vaccines that use established approaches to present influenza proteins to the immune system, it uses messenger RNA, the same basic technology that made headlines during the COVID-19 pandemic.
